482 related articles for article (PubMed ID: 27849377)
21. Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat.
Kabadi UM; Cech R
J Endocrinol Invest; 1997 Jun; 20(6):319-26. PubMed ID: 9294777
[TBL] [Abstract][Full Text] [Related]
22. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.
Vita R; Saraceno G; Trimarchi F; Benvenga S
Endocrine; 2013 Feb; 43(1):154-60. PubMed ID: 22932947
[TBL] [Abstract][Full Text] [Related]
23. Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism.
Brancato D; Scorsone A; Saura G; Ferrara L; Di Noto A; Aiello V; Fleres M; Provenzano V
Endocr Pract; 2014 Jul; 20(7):657-62. PubMed ID: 24449674
[TBL] [Abstract][Full Text] [Related]
24. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W
Clin Endocrinol (Oxf); 2004 Jun; 60(6):750-7. PubMed ID: 15163340
[TBL] [Abstract][Full Text] [Related]
25. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine.
Benvenga S; Di Bari F; Vita R
Endocrine; 2017 Apr; 56(1):138-145. PubMed ID: 28155174
[TBL] [Abstract][Full Text] [Related]
26. Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation.
Morelli S; Reboldi G; Moretti S; Menicali E; Avenia N; Puxeddu E
Endocrine; 2016 Jun; 52(3):571-8. PubMed ID: 26537478
[TBL] [Abstract][Full Text] [Related]
27. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine.
Fallahi P; Ferrari SM; Marchi S; De Bortoli N; Ruffilli I; Antonelli A
Endocrine; 2017 Jul; 57(1):175-178. PubMed ID: 27577569
[No Abstract] [Full Text] [Related]
28. Long term therapy with a new liquid L-thyroxine preparation: bioequivalence with L-T4 tablets.
Carpi A; Toni MG; Maccheroni M; De Gaudio C
Thyroidology; 1992 Dec; 4(3):115-9. PubMed ID: 1285037
[TBL] [Abstract][Full Text] [Related]
29. L-T4 Therapy in Enteric Malabsorptive Disorders.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():626371. PubMed ID: 33708175
[TBL] [Abstract][Full Text] [Related]
30. Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy.
Liewendahl K; Helenius T; Lamberg BA; Mähönen H; Wägar G
Acta Endocrinol (Copenh); 1987 Nov; 116(3):418-24. PubMed ID: 3687325
[TBL] [Abstract][Full Text] [Related]
31. Identification of Resistance to Exogenous Thyroxine in Humans.
Lacámara N; Lecumberri B; Barquiel B; Escribano A; González-Casado I; Álvarez-Escolá C; Aleixandre-Blanquer F; Morales F; Alfayate R; Bernal-Soriano MC; Miralles R; Yildirim Simsir I; Özgen AG; Bernal J; Berbel P; Moreno JC
Thyroid; 2020 Dec; 30(12):1732-1744. PubMed ID: 32498666
[No Abstract] [Full Text] [Related]
32. Retrospective Study of Patients Switched from Tablet Formulations to a Gel Cap Formulation of Levothyroxine: Results of the CONTROL Switch Study.
Ernst FR; Sandulli W; Elmor R; Welstead J; Sterman AB; Lavan M
Drugs R D; 2017 Mar; 17(1):103-115. PubMed ID: 27943146
[TBL] [Abstract][Full Text] [Related]
33. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.
Shimon I; Cohen O; Lubetsky A; Olchovsky D
Thyroid; 2002 Sep; 12(9):823-7. PubMed ID: 12481949
[TBL] [Abstract][Full Text] [Related]
34. Treatment of congenital hypothyroidism: comparison between L-thyroxine oral solution and tablet formulations up to 3 years of age.
Vigone MC; Ortolano R; Vincenzi G; Pozzi C; Ratti M; Assirelli V; Vissani S; Cavarzere P; Mussa A; Gastaldi R; Di Mase R; Salerno M; Street ME; Trombatore J; Weber G; Cassio A
Eur J Endocrinol; 2021 Nov; 186(1):45-52. PubMed ID: 34714772
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.
Persani L; Preziati D; Matthews CH; Sartorio A; Chatterjee VK; Beck-Peccoz P
Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396
[TBL] [Abstract][Full Text] [Related]
36. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients.
Bolk N; Visser TJ; Kalsbeek A; van Domburg RT; Berghout A
Clin Endocrinol (Oxf); 2007 Jan; 66(1):43-8. PubMed ID: 17201800
[TBL] [Abstract][Full Text] [Related]
37. The associations of polymorphisms of TSH receptor and thyroid hormone receptor genes with L-thyroxine treatment in hypothyroid patients.
Al-Azzam SI; Alzoubi KH; Khabour O; Al-Azzeh O
Hormones (Athens); 2014; 13(3):389-97. PubMed ID: 25079464
[TBL] [Abstract][Full Text] [Related]
38. [Bioequivalence of L-thyroxine tablets and a liquid L-thyroxine solution in the treatment of hypothyroid patients].
Grussendorf M; Vaupel R; Wegscheider K
Med Klin (Munich); 2004 Nov; 99(11):639-44. PubMed ID: 15583873
[TBL] [Abstract][Full Text] [Related]
39. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors.
Vita R; Saraceno G; Trimarchi F; Benvenga S
J Clin Endocrinol Metab; 2014 Dec; 99(12):4481-6. PubMed ID: 25259910
[TBL] [Abstract][Full Text] [Related]
40. Oral liquid levothyroxine treatment at breakfast: a mistake?
Cappelli C; Pirola I; Gandossi E; Formenti A; Castellano M
Eur J Endocrinol; 2014 Jan; 170(1):95-9. PubMed ID: 24123095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
